Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway

Documenti analoghi

• Factors associated with response to rituximab in patients with immune thrombocytopenia
  di: Galina Tsykunova, et al.
  Pubblicazione: (2026)
• Anti‐ CD38 therapy in immune thrombocytopenia ( ITP )
  di: Waleed Ghanima, et al.
  Pubblicazione: (2026)
• Longitudinal plasma proteomics in romiplostim‐treated patients with immune thrombocytopenia
  di: Vivianne S. Nelson, et al.
  Pubblicazione: (2025)
• Socioeconomic Position and Chronic Opioid Use After Hip Fracture Surgery: A Danish Population‐Based Cohort Study
  di: Nickolaj Risbo, et al.
  Pubblicazione: (2025)
• Risk of fractures and use of bisphosphonates in adult patients with immune thrombocytopenia—A nationwide population‐based study
  di: Nikolaj Mannering, et al.
  Pubblicazione: (2024)